| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Passage BIO, Inc. | Chief Financial Officer | Common Stock | 5.45K | $4.96K | $0.91 | May 21, 2021 | Direct |
| Carisma Therapeutics Inc. | Chief Financial Officer | Stock Option (Right to Buy) | 85K | Jun 17, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| CARM | Carisma Therapeutics Inc. | Jun 17, 2024 | 1 | $0 | 4 | Jun 18, 2024 | Chief Financial Officer |
| CARM | Carisma Therapeutics Inc. | Jan 31, 2024 | 1 | $0 | 4 | Feb 2, 2024 | Chief Financial Officer |
| CARM | Carisma Therapeutics Inc. | Jun 6, 2023 | 1 | $0 | 4 | Jun 8, 2023 | Chief Financial Officer |
| CARM | Carisma Therapeutics Inc. | Mar 7, 2023 | 1 | $0 | 4 | Mar 9, 2023 | Chief Financial Officer |
| CARM | Carisma Therapeutics Inc. | Mar 7, 2023 | 0 | $0 | 3 | Mar 9, 2023 | Chief Financial Officer |
| PASG | Passage BIO, Inc. | May 21, 2021 | 1 | $30K | 4 | May 21, 2021 | Chief Financial Officer |